{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T22:59:08Z","timestamp":1773097148435,"version":"3.50.1"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T00:00:00Z","timestamp":1667779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background\/Objective<\/jats:title><jats:p>The most significant adverse events following SARS-CoV-2 vaccination are myocarditis and pericarditis. Myositis and dermatomyositis have been reported following SARS-CoV-2 infection, but vaccine-induced dermatomyositis (DM) has not been reported. Our case series aimed to characterize new onset dermatomyositis or disease-related flares following SARS-CoV-2 vaccination.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>A total of 53 patients from our institution with a new or pre-existing diagnosis of DM were recruited and consented. Phone interviews were conducted to obtain vaccination status and symptoms following vaccination. Electronic medical records were reviewed to extract age, sex, autoantibody profiles, comorbidities, immunomodulatory therapies, creatine kinase (CK) values, and SARS-CoV-2 vaccination dates from the provincial vaccination registry. For patients who reported disease flares, records were reviewed for the onset and nature of symptoms, extent of organ involvement and changes in immunomodulation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>On average, patients received 2.62 vaccine doses (range 1\u20133 doses). A total of 3 of 51 patients (5.88%) experienced dermatomyositis symptoms following vaccination. Two patients were newly diagnosed with dermatomyositis, one requiring hospitalization. Reported symptom onset following vaccination ranged from 1 to 30 days. Of note, all of these patients had normal CK values, even though there was muscle biopsy-confirmed myositis in one patient. Eight patients in the cohort (15.1%) had asymptomatic CK elevation (&amp;lt;1.5 X ULN).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>New onset dermatomyositis or flare up of pre-existing dermatomyositis may be a rare complication in SARS-CoV-2 vaccination although no studies can support a true correlation. Several pathophysiologic mechanisms are proposed.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2022.1013378","type":"journal-article","created":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T04:32:41Z","timestamp":1667795561000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["A case series of dermatomyositis following SARS-CoV-2 vaccination"],"prefix":"10.3389","volume":"9","author":[{"given":"Airiss R.","family":"Chan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan Willem","family":"Cohen Tervaert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Desiree","family":"Redmond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elaine","family":"Yacyshyn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Ferrara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter M.","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Osman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Gniadecki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,7]]},"reference":[{"key":"B1","year":"2022","journal-title":"Health InfoBase COVID-19 Vaccination Coverage."},{"key":"B2","doi-asserted-by":"publisher","first-page":"3195","DOI":"10.1007\/s10067-020-05334-7","article-title":"COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series.","volume":"39","author":"Ferri","year":"2020","journal-title":"Clin Rheumatol."},{"key":"B3","year":"2022","journal-title":"Reported Side Effects Following COVID-19 Vaccination in Canada."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1056\/NEJMoa2110737","article-title":"Myocarditis after Covid-19 vaccination in a large health care organization.","volume":"385","author":"Witberg","year":"2021","journal-title":"N Engl J Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.clindermatol.2020.12.013","article-title":"Autoimmune connective tissue diseases in the COVID-19 pandemic.","volume":"39","author":"Dourmishev","year":"2021","journal-title":"Clin Dermatol."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab290","article-title":"Onset of dermatomyositis in close association with COVID-19-a first case reported.","volume":"60","author":"Borges","year":"2021","journal-title":"Rheumatology."},{"key":"B7","first-page":"20","article-title":"Dermatomyositis during COVID-19 pandemic (a case series): is there a cause effect relationship?","volume":"68","author":"Gokhale","year":"2020","journal-title":"J Assoc Physicians India."},{"key":"B8","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jdcr.2021.04.036","article-title":"Dermatomyositis in a COVID-19 positive patient.","volume":"13","author":"Ho","year":"2021","journal-title":"JAAD Case Rep."},{"key":"B9","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.pediatrneurol.2021.05.011","article-title":"Juvenile dermatomyositis triggered by SARS-CoV-2.","volume":"121","author":"Liquidano-Perez","year":"2021","journal-title":"Pediatr Neurol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s10875-021-01119-y","article-title":"Onset and relapse of juvenile dermatomyositis following asymptomatic SARS-CoV-2 infection.","volume":"42","author":"Rodero","year":"2022","journal-title":"J Clin Immunol."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.4931","article-title":"Dermatomyositis-lupus overlap syndrome complicated with cardiomyopathy after SARS-CoV-2 infection: a new potential trigger for musculoskeletal autoimmune disease development.","volume":"9","author":"Shahidi Dadras","year":"2021","journal-title":"Clin Case Rep."},{"key":"B12","doi-asserted-by":"publisher","first-page":"E9","DOI":"10.1002\/mus.27105","article-title":"COVID-19-associated myositis may be dermatomyositis.","volume":"63","author":"Tanboon","year":"2021","journal-title":"Muscle Nerve."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-021-00570-w","article-title":"COVID-19 and myositis; true dermatomyositis or prolonged post viral myositis?","volume":"19","author":"Movahedi","year":"2021","journal-title":"Pediatr Rheumatol Online J."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-212786","article-title":"2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups.","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1093\/rheumatology\/keg427","article-title":"International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease.","volume":"43","author":"Isenberg","year":"2004","journal-title":"Rheumatology."},{"key":"B16","year":"2021","journal-title":"COVID-19 Vaccine Safety: Summary of Weekly Report on Side Effects Following Immunization \u2013 Canada.CA."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.18553\/jmcp.2020.26.11.1424","article-title":"Patient-reported dermatomyositis and polymyositis flare symptoms are associated with disability, productivity loss, and health care resource use.","volume":"26","author":"Christopher-Stine","year":"2020","journal-title":"J Manag Care Spec Pharm."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10081184","article-title":"A large cluster of new onset autoimmune myositis in the yorkshire region following SARS-CoV-2 vaccination.","volume":"10","author":"De Marco","year":"2022","journal-title":"Vaccines."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1007\/s11739-022-03028-3","article-title":"Relapses of idiopathic inflammatory myopathies after vaccination against COVID-19: a real-life multicenter Italian study.","volume":"17","author":"Conticini","year":"2022","journal-title":"Intern Emerg Med."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1186\/s41927-022-00250-6","article-title":"Dermatomyositis post vaccine against SARS-COV2.","volume":"6","author":"Camargo Coronel","year":"2022","journal-title":"BMC Rheumatol."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15749","article-title":"Vaccine-induced dermatomyositis following COVID-19 vaccination.","volume":"35","author":"Chaima","year":"2022","journal-title":"Dermatol Ther."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15479","article-title":"Dermatomyositis following COVID-19 vaccination.","volume":"35","author":"Venkateswaran","year":"2022","journal-title":"Dermatol Ther."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-021-01023-9","article-title":"COVID-19 and myositis: what we know so far.","volume":"23","author":"Saud","year":"2021","journal-title":"Curr Rheumatol Rep."},{"key":"B24","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s10067-015-3073-0","article-title":"Viral RNA in the influenza vaccine may have contributed to the development of ANCA-associated vasculitis in a patient following immunisation.","volume":"35","author":"Jeffs","year":"2016","journal-title":"Clin Rheumatol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s40618-021-01681-7","article-title":"Post-COVID-vaccine autoimmune\/inflammatory syndrome in response to adjuvants (ASIA syndrome) manifesting as subacute thyroiditis.","volume":"45","author":"Das","year":"2022","journal-title":"J Endocrinol Invest."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1007\/s10067-022-06149-4","article-title":"Autoimmune post-COVID vaccine syndromes: does the spectrum of autoimmune\/inflammatory syndrome expand?","volume":"41","author":"Jara","year":"2022","journal-title":"Clin Rheumatol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1007\/s11926-010-0101-6","article-title":"Dermatomyositis and type 1 interferons.","volume":"12","author":"Greenberg","year":"2010","journal-title":"Curr Rheumatol Rep."},{"key":"B28","doi-asserted-by":"publisher","first-page":"5459","DOI":"10.4049\/jimmunol.1002795","article-title":"Type I interferon in the pathogenesis of lupus.","volume":"192","author":"Crow","year":"2014","journal-title":"J Immunol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41586-022-04642-z","article-title":"TLR7 gain-of-function genetic variation causes human lupus.","volume":"605","author":"Brown","year":"2022","journal-title":"Nature."},{"key":"B30","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1007\/s10067-021-05963-6","article-title":"Adverse events and disease flares after SARS-CoV-2 vaccination in patients with systemic lupus erythematosus.","volume":"41","author":"Barbhaiya","year":"2022","journal-title":"Clin Rheumatol."},{"key":"B31","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1007\/s10067-021-05980-5","article-title":"Side effects and flares risk after SARS-CoV-2 vaccination in patients with systemic lupus erythematosus.","volume":"41","author":"Zavala-Flores","year":"2022","journal-title":"Clin Rheumatol."},{"key":"B32","article-title":"COVID-19 vaccination as a potential trigger for new-onset systemic lupus erythematosus.","volume":"14","author":"Kaur","year":"2022","journal-title":"Cureus."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/mrcr\/rxac018","article-title":"Systemic lupus erythematosus and antiphospholipid syndrome after COVID-19 vaccination. A case report.","author":"Molina-Rios","year":"2022","journal-title":"Mod Rheumatol Case Rep."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2016-000294","article-title":"Dermatomyositis flare on imiquimod therapy highlights a crucial role of aberrant TLR7 signalling.","volume":"2","author":"Meyer","year":"2016","journal-title":"RMD Open."},{"key":"B35","doi-asserted-by":"publisher","first-page":"25254","DOI":"10.1073\/pnas.2010722117","article-title":"Superantigenic character of an insert unique to SARS-CoV-2 spike supported by skewed TCR repertoire in patients with hyperinflammation.","volume":"117","author":"Cheng","year":"2020","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.899526","article-title":"Autoimmune skin disease exacerbations following COVID-19 vaccination.","volume":"13","author":"Sprow","year":"2022","journal-title":"Front Immunol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"4794","DOI":"10.4049\/jimmunol.1000702","article-title":"Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines.","volume":"186","author":"Kuznik","year":"2011","journal-title":"J Immunol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1136\/annrheumdis-2020-217522","article-title":"Antibodies against immunogenic epitopes with high sequence identity to SARS-CoV-2 in patients with autoimmune dermatomyositis.","volume":"79","author":"Megremis","year":"2020","journal-title":"Ann Rheum Dis."},{"key":"B39","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1056\/NEJMoa2109730","article-title":"Myocarditis after BNT162b2 mRNA vaccine against Covid-19 in Israel.","volume":"385","author":"Mevorach","year":"2021","journal-title":"N Engl J Med."},{"key":"B40","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1161\/CIRCULATIONAHA.121.056135","article-title":"Myocarditis with COVID-19 mRNA vaccines.","volume":"144","author":"Bozkurt","year":"2021","journal-title":"Circulation."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.1013378\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T04:32:47Z","timestamp":1667795567000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.1013378\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,7]]},"references-count":40,"alternative-id":["10.3389\/fmed.2022.1013378"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.1013378","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,7]]},"article-number":"1013378"}}